PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer

[1] Duijf PHG(2019)Mechanisms of genomic instability in breast cancer Trends Mol Med 25 595-611

[2] Nanayakkara D(2019)Consideration of breast cancer subtype in targeting the androgen receptor Pharmacol Ther 200 135-147

[3] Nones K(2019)Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases Surg Today 10 245-150

[4] Srihari S(2019)Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy Front Endocrinol 114 108800-1112

[5] Kalimutho M(2019)Chemoresistance mechanisms of breast cancer and their countermeasures Biomed Pharmacother 11 1758835919833519-919

[6] Khanna KK(2019)HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance Ther Adv Med Oncol 19 133-88

[7] Venema CM(2019)Recent advances in the clinical development of immune checkpoint blockade therapy Cell Oncol (Dordrecht) 20 1105-D326

[8] Bense RD(2019)Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease Semin Cancer Biol 24 911-81

[9] Steenbruggen TG(2019)The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat Rev Cancer 114 76-106

[10] Nienhuis HH(2019)Expression of PD-L1 attenuates the positive impacts of high-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer Cancer Biol Ther 34 D322-380

[1] Duijf PHG(2019)Mechanisms of genomic instability in breast cancer Trends Mol Med 25 595-611

[2] Nanayakkara D(2019)Consideration of breast cancer subtype in targeting the androgen receptor Pharmacol Ther 200 135-147

[3] Nones K(2019)Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases Surg Today 10 245-150

[4] Srihari S(2019)Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy Front Endocrinol 114 108800-1112

[5] Kalimutho M(2019)Chemoresistance mechanisms of breast cancer and their countermeasures Biomed Pharmacother 11 1758835919833519-919

[6] Khanna KK(2019)HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance Ther Adv Med Oncol 19 133-88

[7] Venema CM(2019)Recent advances in the clinical development of immune checkpoint blockade therapy Cell Oncol (Dordrecht) 20 1105-D326

[8] Bense RD(2019)Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease Semin Cancer Biol 24 911-81

[9] Steenbruggen TG(2019)The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat Rev Cancer 114 76-106

[10] Nienhuis HH(2019)Expression of PD-L1 attenuates the positive impacts of high-level tumor-infiltrating lymphocytes on prognosis of triple-negative breast cancer Cancer Biol Ther 34 D322-380